Grisnilimab
Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA[1].
Product Specifications
CAS Number
[2367001-70-3]
Product Name Alternative
WT1
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/grisnilimab.html
Purity
99.43
Solubility
10 mM in DMSO
Smiles
[Grisnilimab]
Molecular Weight
(146.39 kDa)
References & Citations
[1]Scharnhorst V, et al. WT1 proteins: functions in growth and differentiation. Gene. 2001 Aug 8;273 (2) :141-61.|[2]Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28 (1) :59-66.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6327559-01 0.2 mL
OCT3/4 (C279) (POU5F1, OCT3, OCT4, OTF3, POU domain, class 5, transcription factor 1, Octamer-binding protein 3, Octamer-binding protein 4, Octamer-binding transcription factor 3) (Biotin)
Ask
View Details MBS6327559-02 5x 0.2 mL
OCT3/4 (C279) (POU5F1, OCT3, OCT4, OTF3, POU domain, class 5, transcription factor 1, Octamer-binding protein 3, Octamer-binding protein 4, Octamer-binding transcription factor 3) (Biotin)
Ask
View Details